Comparative bioavailability of two hydrofluoroalkane formulations of formoterol fumarate both delivered by pressurised metered dose inhaler

Abstract

A randomised, open-label, single dose four-period crossover study was performed in healthy male human subjects to compare the pharmacokinetics of formoterol fumarate (CAS 43229-80-7) after inhalation from two different hydrofluoro -alkane (HFA) pressurised metered dose inhaler (pMDI) formulations at two dose levels, 12 and 24 μg. This is the first stud which has evaluated two HFA formulations of formoterol. Fourteen subjects were randomised, of which 13 completed the study. Each subject received in separate periods a single dose of 12 μg or 24 μg of each formulation. Blood samples for determination of formoterol plasma concentrations were taken pre-administration of study treatments and subsequently at 2, 5, 10, 20, 30, 45, 60, 90 min and 2, 3, 4, 6, 8, 12, 24 and 36 h post-administration of the study treatments. The pharmacokinetic profiles of both the formulations were similar in shape and dose-related increase in formoterol plasma concentration was seen at all time points for both the test and reference formoterol HFA formulations between the dose levels 12 μg and 24 μg. Overall the findings indicate that treatment with the test formoterol HFA preparation has lung absorption pattern and systemic exposure comparable to the already licensed reference formoterol HFA preparation.

Key word

Bronchodilator - CAS 43229-80-7 - CAS 73573-87-2 - Formoterol, bioavailability inhalation, pharmacokinetic - Hydrofluoroalkane

• Reference

• 1 Command Paper No. 977; Treaty series 1990 (19): Montreal Protocol. Substances that deplete the ozone layer. Montreal 16 th September 1987.
• 2 D'Souza S. Montreal protocol and essential use exemptions. J Aerosol Med. 1995; 8: 13-7
• 3 Leach CL. Approaches and challenges to use freon propel-lant replacements. Aerosol Sci Technol. 1995; 22: 328-34
• 4 Bartow RA, and Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998; Feb 55 (2) 303-22
• 5 Houghton CM, Langley SJ, Singh SD, Holden J, MoniciPretiAPAcerbi D et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol deliv ered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled crossover study. Br J Clin Pharmacol. 2004; 58: 359-66
• 6 Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della GCioppa. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder Inhalation via aerolizer. Eur J Clin Pharmacol. 1999; 55: 131-8
• 7 Derks MGM, vandenBerg BTJ, vanderZee JS, Braat MCP, van Boxtel CJ. Biphasic effect-time courses in man after formoterol inhalation: eosinopenic and hypokalemia effects and inhibition of allergic reactions. J Pharmacol Exp Ther. 1997; 283: 824-32
• 8 Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med. 2007; 1: 1931-41
• 9 Declaration of Helsinki (lastrevision Edinburgh 2000) and the Notes of Clarification on Paragraphs 29&30 added by WMA General Assembly, Washington (2002) and Tokyo (2004).
• 10 Häussermann S, Acerbi D, Brand P, Herpich C, Poli G, Sommerer K et al. Lung deposition of formoterol HFA (Atimos®/Forair®) in healthy volunteers, asthmatic and COPD patients. J Aerosol Med. 2007; 20 (3) 331-41